Baxter International (BAX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Indivi ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Baxter International (BAX) and Insulet (PODD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-an ...

From a technical perspective, Baxter International (BAX) is looking like an interesting pick, as it just reached a key level of support. BAX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.A useful tool for traders and analysts, the 200-day simple moving average helps determine long-term market trends for stocks, commodities, indexes, and other financial instruments. It moves higher or lower in conjunction with longer-term price performance, and serves as a support ...

Core Viewpoint - The article emphasizes the identification of solid dividend stocks that are expected to provide high and sustainable dividends over the next decade, despite potential challenges in the market [2]. Group 1: Stock Selection Process - The selection process involves filtering from over 7500 U.S. stocks, focusing on those rated 4 or 5 by Morningstar, indicating undervaluation [3]. - Stocks are further filtered based on the presence of an economic moat, which signifies a company's competitive advantage [3]. - The final list includes approximately 30 stocks that have a history of paying and growing dividends for at least five years and yield over 2.5% [3][4]. Group 2: Selected Stocks Overview - Bristol-Myers Squibb Co. (BMY) has a current dividend yield of 5.15% and has reduced long-term debt from $48 billion in 2020 to $32 billion by the end of 2023 [5]. - The Clorox Company (CLX) has improved gross margins to 46.5% from a low of 33% in 2022, despite facing challenges such as competition and inflation [6][7]. - Chevron (CVX) has a dividend yield of over 4.5% and a payout ratio of 52% on earnings, with a five-year dividend growth rate exceeding 6% [8]. - LyondellBasell Industries, NV (LYB) is 17% below its fair value and has a solid balance sheet with a net-debt/adjusted EBITDA multiple of 1.9x [9]. - Medtronic PLC (MDT) has a dividend growth rate of 6.75% over five years and has paid dividends for 47 consecutive years [10]. - Starbucks Corp. (SBUX) generated nearly $36 billion in revenue in 2023 but faced a decline in same-store sales and store traffic [10]. - United Parcel Service (UPS) has a dividend yield of 5.2% and has increased dividends for 14 years, despite facing a 29% decline in operating profits [11]. - U.S. Bancorp (USB) has a forward yield of 4.76% and is nearly 21% below its fair value, following its acquisition of MUFG Union Bank [12]. - Verizon Communications (VZ) has a high dividend yield of close to 6.6% and holds a significant market share in the U.S. postpaid wireless market [14]. - WEC Energy Group, Inc. (WEC) has raised its dividend for 20 consecutive years and plans to invest $23 billion through 2028 [15].

Baxter International, Inc. (BAX) recently announced that it has entered into a definitive agreement to divest its Vantive Kidney Care segment to Carlyle, a global investment firm, for $3.8 billion.In January 2023, Baxter announced its intention to create a standalone kidney care company intended to improve future performance and create value for all stakeholders. In March 2024, Baxter announced that it was in discussions to explore a potential sale of the Kidney Care segment.Following an analysis of the fin ...

Key TakeawaysBaxter shares slid after the company agreed to sell its kidney care division to Carlyle for $3.8 billion in cash.The company plans to use the roughly $3 billion in after-tax proceeds to reduce its debt.Carlyle's investment is being made through a partnership with Atmas Health. Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash. The deal is expected to generate roughly $3 billion ...

Pitchayanan Kongkaew/iStock via Getty Images Introduction 10 months ago, we had advised investors not to get too myopic about the consequences of the early termination of Novo Nordisk’s (NVO) kidney outcome FLOW trial on Baxter International (NYSE:BAX), but rather focus on some of the more favorable tailwinds surrounding the latter. The BAX stock has since continued to coast along just fine and gauging some of the key highlights from the Q2 results which came out yesterday, we feel even more enthused abo ...

Core Insights - Baxter International Inc. reported second-quarter 2024 adjusted EPS of 68 cents, exceeding the Zacks Consensus Estimate of 66 cents by 3% and showing a year-over-year improvement of 23.6% [1] - The company's revenues from continuing operations reached $3.81 billion, reflecting a 3% increase on a reported basis and a 4% increase at constant currency, surpassing the Zacks Consensus Estimate by 1.9% [2] Revenue Details - Revenue growth was driven by positive demand and pricing across various product categories, with shares of Baxter rising 3.9% in pre-market trading following the results [2] - Year-to-date, Baxter's shares have declined by 10.3%, contrasting with the industry's growth of 3.2% and the S&P 500 Index's increase of 9% [2] Segmental Performance - Medical Products & Therapies segment reported total sales of $1.32 billion, up 4% year over year, benefiting from strong demand and pricing, particularly from the Novum IQ infusion pump [3] - Infusion Therapies & Technologies sales were $1.05 billion, up 4% year over year, while Advanced Surgery sales reached $277 million, up 2% [4] - Healthcare Systems and Technologies segment sales totaled $748 million, up 1% year over year, with growth driven by Care & Connectivity Solutions products [5] - Pharmaceuticals segment sales were $602 million, up 9% year over year, primarily due to new product launches and strong demand for Drug Compounding services [6] - Kidney Care segment sales were $1.12 billion, flat year over year but up 3% at constant currency, with plans to spin off this segment into a separate publicly traded company [7] Margin Analysis - Adjusted gross profit was $1.57 billion, a 4.7% increase year over year, with an adjusted gross margin improvement of 70 basis points to 41.2% [8] - Adjusted operating income from continuing operations was $522 million, up 6.7% year over year, with an adjusted operating margin improvement of 50 basis points to 13.7% [8] Future Guidance - For third-quarter 2024, Baxter anticipates sales growth of 3-4% on a reported basis and 4-5% at constant currency, with adjusted EPS expected between 77 cents and 79 cents [9] - For full-year 2024, sales growth is projected at 3% on a reported basis, with adjusted EPS expected in the range of $2.93-$3.01, an increase from previous guidance [10]

Baxter International Inc. (NYSE:BAX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman & Chief Executive Officer Joel Grade - Executive Vice President & Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Securities David Roman - Goldman Sachs Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Danielle Antalffy - UBS Mat ...